JMKX000189

DRUG2 trials

Sponsors

Jemincare, Shanghai Jeyou Pharmaceutical Co., Ltd.

Conditions

CIPN - Chemotherapy-Induced Peripheral NeuropathyLupus Erythematosus, Systemic

Phase 1

Safety and Efficacy of JMKX000189 for Chemotherapy-Induced Peripheral Neuropathy

Not yet recruitingNCT07601386

Shanghai Jeyou Pharmaceutical Co., Ltd.CIPN - Chemotherapy-Induced Peripheral Neuropathy

Start: 2026-05-10End: 2027-06-20Target: 18Updated: 2026-05-22

Phase 2

JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus

JemincareLupus Erythematosus, Systemic

Start: 2023-09-21End: 2025-12-31Target: 48Updated: 2023-10-13